PASSIVE IMMUNOTHERAPY OF CANCER - PERSPECTIVES AND PROBLEMS

被引：9

作者：

BOS, E

BOON, P

KASPERSEN, F

MCCABE, R

机构：

[1] Organon International BV, Oss

[2] Organon Teknika Group, Rockville, MD

来源：

JOURNAL OF CONTROLLED RELEASE | 1991年 / 16卷 / 1-2期

关键词：

ANTIBODY; IMMUNOCONJUGATE; TUMOR; THERAPY; PRODRUG ACTIVATION;

D O I：

10.1016/0168-3659(91)90034-B

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The past decade was witnessed an exponential growth in the field of immunotherapy of cancer. Efforts have been directed to obtain proof of the concept that monoclonal antibodies, by virtue of their specificity in tumour cell recognition, are ideally suitable as carrier molecules of therapeutic agents. To date, the mass studies on targeting of protein toxins, radioisotopes and drugs have not yet seen a break-through to a clinically useful therapy. A review is given on the problems still to be solved in the design of immunoconjugates for clinical use.

引用

页码：101 / 111

页数：11

共 70 条

[1]

Ehrlich, “Chemotherapy” Proc. 17th Int. Congr. Med. (1913), The collected papers of Paul Ehrlich, 3, (1960)

[2]

Fujimori, Covell, Fletcher, Weinstein, Modelling analysis of the global and microscopic distribution of immunoglobulin G, F(ab) 's and Fab in tumors, Cancer Res, 49, pp. 5656-5663, (1989)

[3]

Vriezendorp, Herpst, Leichner, Klein, Order, Polyclonal 90ytrium labelled antiferritin for refractory Hodgkin disease, International Journal of Radiation Oncology*Biology*Physics, 17, pp. 815-821, (1989)

[4]

Kohler, Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, pp. 494-497, (1975)

[5]

de Nardo, de Nardo, O'Grady, Levy, Mills, Macey, McGahan, Miller, Epstein, Pilot studies ofradioimmunotherapy of B cell lymphoma and leukemia using 131I-Lym-1 monoclonal antibody, Antibody, Immunoconjug. Radiopharm., 50, pp. 7-33, (1988)

[6]

Kernan, Byers, Scannon, Mischak, Brochstein, Flomemberg, Dupont, Orleilly, Treatment of Steroid-resistant acute graft vs hostdisease by in vivo administration of an anti-T cell ricin A chain immunotoxin, J. Amer. Med. Assoc., 259, pp. 3154-3157, (1988)

[7]

Dillman, Human antimouse and antiglobulin responses to monoclonal antibodies, Antibody, Immunoconjug. Radiopharm., 3, pp. 1-15, (1990)

[8]

Ledermann, Begent, Bagshawe, Riggs, Searle, Glaser, Green, Dale, Repeated antitumor antibody therapy in man with suppression of the host response by cyclosporine A, Br. J. Cancer, 58, pp. 654-657, (1988)

[9]

Henslee, Byers, Jennings, Thompson, Marciniak, MacDonald, Ramond, Messino, Lomen, Scannon, Reduction of graft vs host disease in recipients of histoincompatible marrow transplant following administration of Xoma-Zyme-H65, Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, (1989)

[10]

Kalofonos, Sivolapenko, Courtenay-Luck, Snook, Hooker, Winter, McKenzie, Taylor-Papadimitriou, Lavender, Epenetos, Antibody guided targeting of non-small lung cancer using 111In-labeled HMFG-1 F (ab)12 fragments, Cancer Res., 48, pp. 1977-1984, (1988)

← 1 2 3 4 5 6 7 →